MR
Therapeutic Areas
AN2 Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AN2-502998 (oral) | Chronic Chagas Disease | Phase 2/3 |
| Epetraborole | Melioidosis | Preclinical/Early Clinical |
| Undisclosed Boron Compounds | NTM Lung Disease (M. abscessus) | Preclinical |
Leadership Team at AN2 Therapeutics
EE
Eric Easom
Co-Founder, President, CEO, Chair of the Board
SC
Sanjay Chanda, Ph.D.
Chief Development Officer
LO
Lucy O. Day
Chief Financial Officer
JE
Josh Eizen
Chief Legal Officer and Chief Operating Officer
VH
Vince Hernandez
Senior Vice President of Research & Head of Chemistry